Administration of Angiotensin-Converting Enzyme Inhibitors and β-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

BACKGROUND. Adjuvant trastuzumab therapy improves the outcome of patients with early breast cancer (EBC) and overexpression of human epidermal growth factor receptor 2 (HER2). However, it is potentially cardiotoxic. This study aims to evaluate the relationship between the use of angiotensin-converti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Oliva, Stefano, Cioffi, Giovanni, Frattini, Silvia, Simoncini, Edda Lucia, Faggiano, Pompilio, Boccardi, Lidia, Pulignano, Giovanni, Fioretti, Agnese Maria, Giotta, Francesco, Lestuzzi, Chiara, Maurea, Nicola, Sabatini, Silvia, Tarantini, Luigi
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399646/
https://ncbi.nlm.nih.gov/pubmed/22673631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0445
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky